Fresenius SE & Co. (OTCMKTS:FSNUY) Releases Earnings Results, Beats Expectations By $0.03 EPS

Fresenius SE & Co. (OTCMKTS:FSNUY) issued its earnings results on Wednesday. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03, Zacks reports. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.

Fresenius SE & Co. Stock Up 6.3%

Shares of FSNUY stock traded up $0.85 during mid-day trading on Wednesday, hitting $14.46. 27,484 shares of the stock traded hands, compared to its average volume of 167,317. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market cap of $32.58 billion, a P/E ratio of 18.30 and a beta of 0.63. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $17.60. The stock’s fifty day moving average is $12.89 and its two-hundred day moving average is $12.86.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on FSNUY shares. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Wednesday, October 28th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.